Clinical Scorecard: Is Urgent Evaluation Necessary for Non-Visible Haematuria? Insights from a Retrospective Cohort Analysis at a University Teaching Hospital
At a Glance
Category
Detail
Condition
Non-visible haematuria (NVH)
Key Mechanisms
Presence of blood in urine detected by dipstick testing without visible haematuria; potential indicator of urological cancers or benign urological conditions
Target Population
Patients presenting with new onset NVH, typically aged ≥16 years, referred from primary care
Care Setting
Primary care for initial detection; secondary care urology services for further evaluation
Key Highlights
Prevalence of NVH is approximately 2.5% in the general population with variability by age and gender.
Urological cancer was diagnosed in 4.8% of patients with NVH; bladder cancer was the most common (3.8%).
Age ≥60 years and history of smoking are significant risk factors for urological cancer in NVH patients.
Guideline-Based Recommendations
Diagnosis
Use urine dipstick testing as a feasible and cost-effective initial screening tool for NVH in general practice.
Define NVH as dipstick positive for 3+ blood on two consecutive urine samples 1–2 weeks apart, excluding urinary tract infection.
Perform clinical history, renal function tests, upper tract imaging (ultrasound or CT), and flexible cystoscopy for assessment.
Exclude urinary tract infection before flexible cystoscopy; defer cystoscopy until after treatment if UTI is present.
Management
Urgent referral recommended for patients aged ≥60 years with dysuria or raised white cell count per NICE guidelines.
Non-urgent referral for patients aged ≥60 years with unexplained NVH without other risk factors.
Tailor investigations based on patient risk factors to optimize resource use and reduce burden on secondary care.
Monitoring & Follow-up
Follow-up electronic records and imaging for at least 9 months in patients with no malignancy at initial investigation to detect missed cancers.
Risks
Risk of missing urological cancers if urgent evaluation is not performed in high-risk groups (age ≥60, smokers).
Resource and cost implications of full NVH assessment in all patients regardless of risk.
Patient & Prescribing Data
525 patients referred with new onset NVH; median age 66 years; 43.4% male; 47% with smoking history.
Flexible cystoscopy and imaging are mainstays of investigation; antibiotic treatment for UTI prior to cystoscopy when indicated.
Clinical Best Practices
Confirm NVH diagnosis with repeat dipstick testing excluding UTI before referral.
Prioritize urgent evaluation for patients aged ≥60 years and those with smoking history due to higher malignancy risk.
Use a combination of ultrasound and CT imaging selectively based on prior imaging and clinical context.
Defer flexible cystoscopy until after UTI treatment to avoid false positives and procedural complications.
Incorporate detailed clinical history including smoking status, LUTS, and prior cancer history in risk stratification.
